Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02610

Properdin: a novel target for neuroprotection in neonatal hypoxic-ischaemic brain injury

 Claudia Sisa1, Qudsiyah Agha-Shah1,  Balpreet Sanghera1, Ariela Carno1,  Cordula M. Stover2 and  Mariya Hristova1, 3*
  • 1Institute for Women’s Health, Faculty of Population Health Sciences, University College London, United Kingdom
  • 2Department of Infection, Immunity and Inflammation, University of Leicester, United Kingdom
  • 3University College London, United Kingdom

Background: Hypoxic-ischaemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with global incidence of 3 per 1000 live births. Intrauterine or perinatal complications, including maternal infection constitute a major risk for the development of neonatal HI brain damage. During HI inflammatory response and oxidative stress occur, causing subsequent cell death. The presence of an infection sensitises the neonatal brain making it more vulnerable to the HI damage. Currently, therapeutic hypothermia is the only clinically approved treatment available for HI encephalopathy, however it is only partially effective in HI alone and its application in infection-sensitised HI is debatable. Therefore, there is an unmet clinical need for the development of novel therapeutic interventions for the treatment of HI.
Such an alternative is targeting the complement system. Properdin, which is involved in stabilisation of the alternative pathway convertases, is the only known positive regulator of alternative complement activation. Absence of the classical pathway in the neonatal HI brain is neuroprotective. However, there is paucity of data on the participation of the alternative pathway and in particular the role of properdin in HI brain damage.
Objectives: Our study aimed to validate the effect of global properdin deletion in two mouse models: HI alone and LPS-sensitised HI thus addressing two different clinical scenarios.
Results: Our results indicate that global properdin deletion in a Rice-Vannucci model of neonatal HI and LPS-sensitised HI brain damage, in the short term, clearly reduced forebrain cell death and microglial activation, as well as tissue loss. In HI alone, deletion of properdin reduced TUNEL+ cell death and microglial post-HI response at 48h post insult. Under the conditions of LPS-sensitised HI, properdin deletion diminished TUNEL+ cell death, tissue loss and microglial activation at 48h post-HI.
Conclusion: Overall, our data suggests a critical role for properdin, and possibly also a contribution in neonatal HI alone and in infection-sensitised HI brain damage. Thus, properdin can be considered a novel target for treatment of neonatal HI brain damage.

Keywords: Properdin, complement, alternative pathway, hypoxia, ischaemia, Neuroprotection, neonate, Infection

Received: 31 Mar 2019; Accepted: 21 Oct 2019.

Copyright: © 2019 Sisa, Agha-Shah, Sanghera, Carno, Stover and Hristova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Mariya Hristova, University College London, London, United Kingdom, m.hristova@ucl.ac.uk